Squibb Diagnostics' Cardio Tec (Tc 99m teboroxime)
Executive Summary
Radioactive forms of the myocardial perfusion agent will be distributed exclusively by radiopharmacies operator Syncor. Under the agreement, Squibb will sell non-radioactive forms of Cardio Tec to medical centers that perform their own radioactive compounding. Cardiotec was recommended for approval Nov. 17 by the FDA Radiopharmaceutical Committee for use in distinguishing normal from abnormal myocardium in patients with suspected coronary artery disease.